Effects of concomitant use of doxifluridine, radiotherapy and immunotherapy in patients with advanced cervical cancer.
Clinical effects of doxifluridine (group A, 600 mg/body/day; group B, 800 mg/body/day) combined with radiotherapy and immunotherapy were evaluated in patients with advanced cancer of the uterine cervix. Response rates were 84.2% (16/19 patients) in group A and 100% (18/18 patients) in group B, respectively (p=0.230). There was no significant difference in adverse reaction incidence between the methods but significantly higher grade adverse reaction were observed in group B than in group A (p=0.048). Time to progression (TTP) was longer in group B than in group A (p=0.081). The optimal 5'-DFUR dose was 800 mg/body (group B), by which higher grade adverse reactions were fully controlled and TTP was prolonged.
Yamamoto
K
K
Department of Obstetrics and Gynecology, Kinki University School of Medicine, Osakasayama, Osaka 590-0132, Japan. yamamoto@sakai.med.kindai.ac.jp
Noda
K
K
Hatae
M
M
Kudo
T
T
Hasegawa
K
K
Nishimura
R
R
Honjo
H
H
Yajima
A
A
Sato
S
S
Mizutani
K
K
Yakushiji
M
M
Terashima
Y
Y
Ochiai
K
K
Sasaki
H
H
Ozaki
M
M
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005467:Floxuridine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012566:Sizofiran / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*
D000970:Antineoplastic Agents; D005467:Floxuridine; D012566:Sizofiran; C025034:doxifluridine